Get Up to 25% Discount On Each Order
- Brand Name: Kryxana
- Active Ingredient: Ribociclib
- Manufacturer Company Name: Novartis AG
- Strength : 200 mg
- Supplied as: Pack of 21 tablets
- Route of Administration : Oral
A Medication that has cost breast cancer sufferers more than $100,000 a year will be available to patient between $500.00 and $525.00 per pack at Drugssquare.com. Millions of patients with inoperable or metastatic HR-Positive/HER2-Negative breast cancer will benefit from the listing of Ribociclib Kryxana 200 mg.
“The listing means that no woman newly diagnosed with hormone receptor (HR) positive, HER2-negative metastatic breast cancer will hear the words, ‘your breast cancer has spread’, followed by, ‘treatment may cost you up to $8000 per month’.”
What does HR-Positive/HER2-Negative mean?
HR-Positive – Hormone receptor-positive, or HR-positive, breast cancer grows in response to the hormones estrogen and progesterone. These hormones are chemicals produced by glands in the body. Normally, these hormones help regulate body cycles, like menstruation. Estrogen and Progesterone occur naturally in the body and prompt cell action in our system in different ways. Most (about 70 percent) breast cancers are hormone receptor-positive . Among older women, this percentage is even higher.
HER2-Negative – HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2. If breast cancer cells don’t contain HER2 (human epidermal growth factor receptor 2), the condition is called HER2-negative breast cancer. About 20 percent of newly diagnosed breast cancers are HER2-positive.
Ribociclib From Novartis : A Breakthrough Medicine for HR+/HER2- Premenopausal Breast Cancer
The FDA has granted Ribociclib a breakthrough therapy designation for use in combination with an aromatase inhibitor (AI) as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer. Ribociclib is only the second CDK 4/6 inhibitor to be FDA-approved. The other is Palbociclib.
“In clinical trials, Ribociclib Kryxana have made a huge difference to women’s lives – slowing down tumour growth for nearly a year, and delaying the need for chemotherapy with all its potentially debilitating side-effects. These drugs have allowed women to live a normal life for longer.”
Kryxana is a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cyclin-dependent kinases 4 and 6 are two proteins that cause tumor cells in some breast cancers to grow. CDK 4/6 inhibitors like Kryxana work by blocking CDK 4 and 6 from telling cancer cells to multiply. This can slow the growth or spread of cancer cells.
How should you take Kryxana?
- Kryxana is taken by mouth, in tablet form, and can be taken with or without food. This medicine is given in a 28-day treatment cycle. You will take the medicine for the first 21 days of each cycle, followed by 7 days off. Your doctor will determine how long to treat you with Ribociclib.
- It should be taken around the same time each day, preferably in the morning.
- If you vomit after taking a dose or forgets to take a dose, do not take another dose on that day. Take your next dose at your regular time.
- It is important to make sure you are taking the correct amount of medication every time. Before every dose, check that what you are taking matches what you have been prescribed.
- The blood levels of this medication can be affected by certain foods and medications, so they should be avoided. Foods to avoid include pomegranate, pomegranate juice, grapefruit and grapefruit juice. This medication can also interact with medications that prolong the QT interval. Speak to your provider about all medications, including those that are prescribed or over the counter medications, vitamins and supplements you are taking.
- Prior to starting this medication, you will have an electrocardiogram done and lab work to check your complete blood count and liver function. These tests will be repeated throughout your treatment with this medication.
Special Information for Women
Kryxana is not recommended for use during pregnancy; it may harm a fetus. It is unknown if this cancer medication passes into breast milk. Because of the potential for serious adverse reactions in breastfeeding babies, breastfeeding is not recommended while taking Kryxana.
Place your order online or send your enquiry at email@example.com to buy :
KYRXANA tablet in South East Asia – China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KYRXANA tablet in United Arab Emirates – Iran, Saudi Arabia, Jordan.
KYRXANA tablet in North America – United States of America (USA).
KYRXANA tablet in South America – Peru, Venezuela.
KYRXANA tablet in Europe – Romania, Switzerland, Georgia, Italy, UK, Ukraine, Azerbhaijan, Latvia.
KYRXANA tablet in Russia – Moldova, Uzbekistan, Mongolia.
KYRXANA tablet in African Countries – Zimbabwe.
KYRXANA tablet in Australia and New Zealand.
|Continue to Site|
“Our mission is to make medication inexpensive, clearly priced and easy to purchase.”